Page last updated: 2024-12-11

anibamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

anibamine: a pyridine quaternary alkaloid from Aniba sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Anibagenus[no description available]LauraceaeA family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH]

Cross-References

ID SourceID
PubMed CID6479877
CHEMBL ID469649
CHEMBL ID1186558
MeSH IDM0470207

Synonyms (7)

Synonym
anibamine
1h-indolizinium, 6,8-di-(1z)-1-decenyl-2,3-dihydro-5,7-dimethyl-
6,8-bis[(z)-dec-1-enyl]-5,7-dimethyl-2,3-dihydro-1h-indolizin-4-ium
bdbm50242053
6,8-didec-(1z)-enyl-5,7-dimethyl-2,3-dihydro-1h-indolizinium trifluoroacetic acid salt
CHEMBL469649 ,
CHEMBL1186558

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's6 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.91 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.40 (0.95)

This Compound (23.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]